Company intelligence / Profile preview
Norroy Bioscience
Wuxi, Jiangsu, Chinanorroybioscience.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Norroy Bioscience has multiple radiopharmaceutical candidates in clinical development, with three programs in Phase 2 clinical trials. Their lead candidates include 177Lu-NY108 for PSMA-Positive Prostatic Cancer, 68Ga-NY104 for Renal Cell Carcinoma, and 68Ga-NYM032 for Prostatic Cancer.
- Therapeutic areas
- Oncology
- Modalities
- Therapeutic radiopharmaceuticalsDiagnostic radiopharmaceuticalsRadionuclide Drug Conjugates (RDC)Chemical drugs
- Industry
- Biotech
02
Drug pipeline
14 assets13 more assets in the full pipeline.
Beyond the preview
Go deeper on Norroy Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Norroy Bioscience.